Results 51 to 60 of about 15,566 (231)
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.
Seongmee Jeong +13 more
wiley +1 more source
Pharmacogenetics may influence tacrolimus daily dose, but not urinary tubular damage markers in the long-term period after renal transplantation [PDF]
Journal of Medical Biochemistry, 2015 Background: The primary goal of this study was to evaluate the influence of cytochrome P450 (CYP) 3A5 (6986A>G) and ABCB1 (3435C>T) polymorphisms on tacrolimus (TAC) dosage regimen and exposure.
Stefanović Nikola Z. +6 more
doaj
Annals of Human Biology, 2018 Background: CYP3A5 is the predominant sub-family of biotransformation enzymes in the liver and the genetic variations in CYP3A5 are an important determinant of inter-individual and inter-ethnic differences in CYP3A-mediated drug disposition and response.
Geik Yong Ang +9 more
doaj +1 more source
Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. [PDF]
PLoS ONE, 2014 Tacrolimus (TAC) is the backbone of an immunosuppressive drug used in most solid organ transplant recipients. A single nucleotide polymorphism (SNP) at position 6986G>A in CYP3A5 has been notably involved in the pharmacokinetic variability of TAC.
Yi-kuan Chen +7 more
doaj +1 more source
Prevalence of common disease-associated variants in Asian Indians [PDF]
, 2008 Background Asian Indians display a high prevalence of diseases linked to changes in diet and environment that have arisen as their lifestyle has become more westernized.
Trevor J Pemberton +6 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore +16 more
wiley +1 more source
Pharmacokinetic and Pharmacogenetic aspects of drug-drug interactions between antiretroviral and anti-tuberculosis drugs in Ethiopian patients: Implication for optimization of TB-HIV co-treatment [PDF]
, 2013 TB and HIV are immuno-pathologically interacting epidemic infectious diseases affecting the lives of millions globally & sub-Saharan African region accounts the highest burden of both diseases.
Habtewolde Eyakem, Abiy
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor +12 more
wiley +1 more source
Association Between the CYP3A5 Genotype and Blood Pressure [PDF]
Hypertension, 2005 We tested the hypothesis that the presence of a CYP3A5 * 1 allele is associated with increases in blood pressure in 2 studies of subjects with a total of 683 participants. The first study involving 271 subjects was part of a longitudinal study conducted at Indiana University Medical Center ...
Herbert, Ho +10 more
openaire +2 more sources
Frequency of the most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia [PDF]
Makedonsko Farmacevtski Bilten, 2012 The genetic polymorphism affecting the CYP3A5 enzyme is responsible for inter-individual and interethnic variability in the metabolism of CYP3A5 substrates.
Krume Jakovski +3 more
doaj